Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership
Executive Summary
Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements